Gilead Sciences has submitted marketing authorization applications to the European Medicines Agency (EMA) for lenacapavir HIV prevention, a twice-yearly injectable pre-exposure prophylaxis (PrEP) for HIV prevention. This ...
When you partner with Syenza, it’s like a Nuclear Fusion.
Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in
health policy, health economics, systems analysis, public finance, business, and project management.
You’ll also feel our high-impact global and local perspectives with cultural intelligence.